Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression

Nutritional Neuroscience

Volumn 17, Issue 2, 2014, Pages 65-71

  Ranjbar, Elham ^a   Shams, Jamal ^a   Sabetkasaei, Masoumeh ^a   M Shirazi, Minoo ^a   Rashidkhani, Bahram ^a   Mostafavi, Ali ^b   Bornak, Eiliyaz ^a   Nasrollahzadeh, Javad ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HDRS; Major depression; SSRI; Zinc

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYTOKINE; FLUOXETINE; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; ZINC SULFATE;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN INTAKE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; ZINC SUPPLEMENTATION;

HDRS; MAJOR DEPRESSION; SSRI; ZINC;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; INTERLEUKIN-6; IRAN; MALE; MIDDLE AGED; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; ZINC;

EID: 84883505729     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830513y.0000000066     Document Type: Article

References (56)

1. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92.
2. Sadeghirad B, Haghdoost AA, Amin-Esmaeili M, Ananloo ES, Ghaeli P, Rahimi-Movaghar A, et al. Epidemiology of major depressive disorder in Iran: a systematic review and meta-analy-sis. Int J Prev Med 2010;1(2):81-91.
3. Bitanihirwe BK, Cunningham MG. Zinc: the brain's dark horse. Synapse 2009;63(11):1029-49.
4. Maes M, D'Haese PC, Scharpe S, D'Hondt P, Cosyns P, De Broe ME. Hypozincemia in depression. J Affect Disord 1994;31(2): 135-40.
5. Siwek M, Dudek D, Schlegel-Zawadzka M, Morawska A, Piekoszewski W, Opoka W, et al. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord 2010;126(3):447-52.
6. Maserejian NN, Hall SA, McKinlay JB. Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey. J Affect Disord 2012;136(3):781-8.
7. Kroczka B, Branski P, Palucha A, Pilc A, Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull 2001;55(2):297-300.
8. Szewczyk B, Poleszak E, Wlaz P, Wrobel A, Blicharska E, Cichy A, et al. The involvement of serotonergic system in the anti-depressant effect of zinc in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(2):323-9.
9. Franco JL, Posser T, Brocardo PS, Trevisan R, Uliano-Silva M, Gabilan NH, et al. Involvement of glutathione, ERK1/2 phosphorylation and BDNF expression in the antidepressant-like effect of zinc in rats. Behav Brain Res 2008;188(2):316-23.
10. Szewczyk B, Sowa M, Czupryn A, Wieronska JM, Branski P, Sadlik K, et al. Increase in synaptic hippocampal zinc concentration following chronic but not acute zinc treatment in rats. Brain Res 2006;1090(1):69-75.
11. Sowa-Kucma M, Kowalska M, Szlosarczyk M, Golembiowska K, Opoka W, Bas B, et al. Chronic treatment with zinc and anti-depressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortex. Amino Acids 2011;40(1):249-58.
12. Nowak G, Schlegel-Zawadzka M. Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. Biol Trace Elem Res 1999;67(1):85-92.
13. Szewczyk B, Branski P, Wieronska JM, Palucha A, Pilc A, Nowak G. Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol 2002;54(6): 681-5.
14. Cieslik K, Klenk-Majewska B, Danilczuk Z, Wrobel A, Lupina T, Ossowska G. Influence of zinc supplementation on imi-pramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol Rep 2007;59(1):46-52.
15. Cunha MP, Machado DG, Bettio LE, Capra JC, Rodrigues AL. Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8): 1913-20.
16. Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacol Rep 2005;57(6):713-8.
17. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurode-generative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(3):693-701.
18. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(Suppl. 6): 4-6.
19. Raedler TJ. Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 2011;24(6):519-25.
20. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cyto-kines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31(10): 2121-31.
21. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36(2):764-85.
22. Barrondo S, Salles J. Allosteric modulation of 5-HT(1A) receptors by zinc: binding studies. Neuropharmacology 2009;56(2): 455-62.
23. Oxenkrug GF. Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci 2007;1122:35-49.
24. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71(2):171-86.
25. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67(5):446-57.
26. Hiles SA, Baker AL, de Malmanche T, Attia J. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 2012;26(7):1180-8.
27. Foster M, Samman S. Zinc and regulation of inflammatory cyto-kines: implications for cardiometabolic disease. Nutrients 2012; 4(7):676-94.
28. Kerschensteiner M, Gallmeier E, Behrens L, Leal V, Misgeld T. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?. J Exp Med 1999;189:865-70.
29. Schinder A, Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 2000;23:639-45.
30. Huang E, Reichardt L. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24: 677-736.
31. Sen S, Duman R, Sanacora G. Serum brain-derived neuro-trophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64(6): 527-32.
32. Mlyniec K, Budziszewska B, Reczynski W, Sowa-Kucma M, Nowak G. The role of the GPR39 receptor in zinc deficient-animal model of depression. Behav Brain Res 2013;238:30-5.
33. Nowak G, Legutko B, Szewczyk B, Papp M, Sanak M, Pilc A. Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. Eur J Pharmacol 2004;492(1):57-9.
34. Sowa-Kucma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, et al. Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm 2008; 115(12):1621-8.
35. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14(3):347-53.
36. Beller EM, Gebski V, Keech AC. Randomisation in clinical trials. Med J Aust 2002;177(10):565-7.
37. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Polish J Pharmacol 2003;55(6):1143-7.
38. Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 2009;118(1-3):187-95.
39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
40. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6(4):278-96.
41. Miller IW, Bishop S, Norman WH, Maddever H. The Modified Hamilton Rating Scale for Depression: reliability and validity. Psychiatry Res 1985;14(2):131-42.
42. Vieweg WV, Hasnain M, Lesnefsky EJ, Pandurangi AK. Review of major measuring instruments in comorbid depression and coronary heart disease. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(4):905-12.
43. McGuirk J, Silverstone T. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 1990;14(4):361-72.
44. Foltin RW, Haney M, Comer SD, Fischman MW. Effect of fluoxetine on food intake of humans living in a residential laboratory. Appetite 1996;27(2):165-81.
45. Greeno CG, Wing RR. A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr 1996; 64(3):267-73.
46. Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxi-dative stress. Am J Clin Nutr 2007;85(3):837-44.
47. Bao B, Prasad AS, Beck FW, Fitzgerald JT, Snell D, Bao GW, et al. Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr 2010;91(6):1634-41.
48. Hannestad J, DellaGioia N, Bloch M. The effect of antidepress-ant medication treatment on serum levels of inflammatory cyto-kines: a meta-analysis. Neuropsychopharmacology 2011;36(12): 2452-9.
49. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008;11(8):1169-80.
50. Huang TL, Lee CT, Liu YL. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 2008;42(7):521-5.
51. Corona C, Masciopinto F, Silvestri E, Viscovo AD, Lattanzio R, Sorda RL, etal. Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death Dis 2010;1:e91.
52. Hwang JJ, Park MH, Choi SY, Koh JY Activation of the Trk signaling pathway by extracellular zinc. Role of metalloproteinases. J Biol Chem 2005;280(12):11995-2001.
53. Kyeremanteng C, James J, Mackay J, Merali Z. A study of brain and serum brain-derived neurotrophic factor protein in Wistar and Wistar-Kyoto rat strains after electroconvulsive stimulus. Pharmacopsychiatry 2012;45(6):244-9.
54. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002;7(Suppl 1):S71-80.
55. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64.
56. Paoletti P, Vergnano AM, Barbour B, Casado M. Zinc at glutamatergic synapses. Neuroscience 2009;158(1):126-36.